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ABSTRACT
This study examines the influence of melatonin on the PC anticoagulant pathway in rats. The experi-
ment was performed on 52 male white Wistar rats weighing 200-220 g. Animals were equally divided into 
4 groups. They were treated in three consecutive days, every 12 hours, subcutaneously: 1st group – with sa-
line solution (solvent for melatonin and luzindole); 2nd group – with melatonin, daily dose 0.2 mg/kg body 
weight; 3rd group – with luzindole, nonstop dose of 0.4 mg/kg body weight; 4th group – melatonin, one hour 
after pretreatment with luzindole. The required amount of blood was taken under urethane narcosis via di-
rect cardiac puncture. After three days of administration of melatonin, a significant decrease in the antigen 
concentration of protein C, protein C activity, activated protein C and thrombomodulin was observed. The 
soluble form of the endothelial receptor for protein C, activity of protein S and free protein S were signifi-
cantly elevated. The competitive melatonin receptor antagonist – luzindole, when administered alone and 
in pretreatment, effectively removes the observed effects of melatonin by blocking exogenous, as well as en-
dogenous melatonin. In conclusion, our data give us reason to assume that melatonin significantly reduces 
the activity of the protein C anticoagulant pathway in rats.
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INTRODUCTION
Hemostasis is a process with a strong protective 
effect and results from the balance between the co-
agulant, anticoagulant and fibrinolytic systems. One 
of the important mechanisms of the anticoagulation 
system is the protein C (PC) anticoagulant pathway, 
which includes membrane proteins and circulating 
proteins: PC, thrombomodulin, endothelial protein 
C receptor (EPCR) and protein S (1). They form a 
multimolecular complex that provides efficient pro-
teolysis of substrates, anticoagulant and cytoprotec-
tive effects (2,3). Like all systems in the body, hemo-
stasis is subject to complex regulatory effects, and 
more and more evidence is accumulated about the 
significant role of the endocrine system (4,5).
The effects of melatonin on hemostasis are rela-
tively poorly studied. Literary data suggest that mel-
atonin indubitably affects processes related to hemo-
stasis in both experimental conditions and clinical 
observations. It should be noted that experimental 
studies are conducted on animal models with vari-
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ous disabilities, rather than intact animals, which 
complicates the assessment of results (6). Clinical ob-
servations are based on tracking the individual pa-
rameters of hemostasis in patients with different pri-
mary diseases and comorbidities, which determines 
the contradictory nature of the conclusions (7,8).
Deriving from the exposition so far, as well as 
our previous publications (9,10,11) related to study-
ing melatonin’s effects on hemostasis, which prove 
an irrevocable tendency towards heightened coagu-
lation, it is only logical to raise the question of mel-
atonin’s place and role in the anticoagulant system. 
Based upon these thoughts we’ve set it as our goal to 
study the effects of melatonin on key parameters of 
the protein C anticoagulant pathway, which consti-
tutes a primary part of the anticoagulant system. 
MATERIAL AND METHODS
The experiment was conducted upon 52 male 
white Wistar rats, weighing 200-220g, in accordance 
with the European Convention for protection of ex-
perimental animals (Protection of animals used for 
experimental purposes, Council Directive 86/609/
EEc of November 1986, Directive 2010/63/EU of the 
European Parliament and of the Council of Septem-
ber 2010). Animals were housed under standard con-
ditions, with free access to standard pellet food and 
water ad libitum, with a 12-hour light/dark cycle.
Animals were divided into four equal groups – 
one control and three experimental. Treatment was 
administered subcutaneously over a span of three 
consecutive days, twice a day, over 12 hour intervals. 
The first (control) group was injected with saline – 
a solvent of melatonin and luzindole, with the same 
schedule and amount per kg body weight, the second 
group – with melatonin (Merk, Germany) in a daily 
dose of 0.2mg/kg body weight, the third group – with 
luzindole (Sigma Chemicals/St. Louis, MO, USA) in a 
daily dose of 0.4mg/kg body weight, the fourth group 
– with melatonin one hour after pretreatment with 
luzindole, using the same procedure and dosages.
The required amount of blood was taken under 
urethane anesthesia by cardiac puncture in dispos-
able syringes. Sodium nitrate was used as anticoag-
ulant (0.11 mol/l); in a blood to citrate ratio 9:1. The 
citrate blood was centrifuged for 10 minutes at 3000 
revolutions/minute. The citrated plasma was frozen 
Fig. 1. Effects of melatonin (0.2mg/kg body weight), luz-
indole (0.4mg/kg body weight) and melatonin 1 hour after 
pretreatment with luzindole (same dose), all administered 
s.c. to male Wistar rats, 2 times a day, for three consecu-
tive days on (PC: Ag) (A), (PC: Act) (B) and (APC: Ag) 
(C). Used abbreviations: C - control group injected saline; 
M - melatonin; L - luzindole. Data are presented as x ±S
x , ***- p <0.001; **- p <0.01.
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at –60ºC and the parameters were determined by the 
tenth day.
The majority of the analyzed parameters were 
determined by an ELISA method with a kit of Diag-
nostica Stago (France), with the exception of throm-
bomodulin, determined by an IMUBIND®ELISA kit, 
American Diagnostica Inc., USA.
All data were processed via variation analysis 
utilizing the student-fisher t-test. Values of p <0.05 
were considered statistically significant.
RESULTS
1. Effects of melatonin and luzindole on plas-
ma levels of PC antigen (PC: Ag), PC activ-
ity (PC: Act) and activated PC (APC: Ag). 
From Figure 1A it is evident that melatonin 
reduces the plasma level of PC antigen from 
2.85±0.21μg/ml (control group) to 1.31±0.16μg/
ml (p<0.001). After administration of luz-
indole only, as well as after pretreatment with 
it, an increase in PC: Ag is observed, the reg-
istered values were respectively 4.15±0.35μg/
ml (p<0.01) and 4.05±0.34μg/ml (p<0.01). 
We note a significant reduction in PC activi-
ty (%) in the animals treated with melatonin – 
down to 50.13 ± 6.98 (p <0.001), as demonstrated 
in Fig. 1B. PC activity increases to 161.70±12.91 
(p<0.01) after the application of luzindole, while 
pretreatment with luzindole increases it up to 
169.70±9.83 (p<0.01). The value of PC activity in 
the control group of animals was 115.20±9.72. 
The changes in the levels of activated protein C 
under the effect of melatonin and luzindole are 
presented in Fig. 1C. It is evident that melatonin 
significantly decreases APC from 0.79±0.04ng/
ml (control group) to 0.42±0.04ng/ml (p<0.001). 
Luzindole, in its turn, increases APC up to 
1.17±0.10ng/ml (p<0.01). Melatonin, adminis-
tered after pretreatment with luzindole also in-
creases APC to 1.28±0.07ng/ml (p<0.001).
2. Effects of melatonin and luzindole on 
the levels of soluble protein C recep-
tor (sEPCR) and thrombomodulin. 
Fig. 2A shows that the three-day administra-
tion of melatonin leads to an increase in sEP-
CR from 118.40±6.36ng/ml (control group) to 
169.20±13.86ng/ml (p <0.01). After administra-
tion of luzindole only, as well as after pretreat-
ment with it, a decrease in sEPCR was observed, 
with registered values relative to the control 
group of animals of 50.19±4.00ng/ml (p<0.001) 
and 39.69±5.51ng/ml (p<0.001), respectively. 
Fig. 2B shows the effect of melatonin on the level 
of thrombomodulin and we can see a reduction 
from 6.26±0.48ng/ml (control group) down to 
2.62±0.16ng/ml (p<0.001). The stand-alone ap-
plication of luzindole increases thrombomod-
ulin to 9.72±0.79 ng/ml (p<0.01). Pretreatment 
with luzindole shows a more pronounced in-
crease in thrombomodulin to 9.67±0.54ng/ml 
(p<0.001).
Fig. 2. Effects of melatonin (0.2 mg/kg body weight), luzindole (0.4 mg/kg body weight) and melatonin 1 hour after pre-
treatment with luzindole (same dose), all administered s.c. to male Wistar rats, 2 times a day, for three consecutive days 
on sEPCR (A) and thrombomodulin (B). Used abbreviations: C - control group injected saline; M - melatonin;  
L - luzindole. Data are presented as x ±S x , ***- p <0.001; **- p <0.01.
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3. Effects of melatonin and luzindole on 
the levels of free protein S antigen (free 
PS: Ag) and protein S activity (PS: Act). 
The results presented in Fig. 3A show 
that the three-day administration of mel-
atonin increases free protein S levels 
from 6.81±0.53 μg/ml (control group) to 
9.77±0.68μg/ml (p<0.01). Luzindole reduc-
es the levels of free protein S to 3.02±0.39μg/
ml (p<0.001). Pretreatment with luzindole re-
peats this effect and the decrease in free pro-
tein S is down to 3.65±0.25μg/ml (p<0.001). 
Fig. 3B shows the changes in the protein S ac-
tivity (%). The three-day administration of 
melatonin increases the protein S activity to 
171.50±9.92 (p<0.001). Luzindole and pretreat-
ment with it reduce the protein S activity to 
42.33±5.44 (p <0.001) and 50.31±4.16 (p<0.001), 
respectively. The value of protein S activity in 
the control group of animals was 105.80±9.73.
DISCUSSION
Protein C – a vitamin K-dependent glycopro-
tein plays a key role in the protein C anticoagu-
lant pathway, synthesized in hepatocytes and circu-
lating in plasma as an inactive zymogen. It is acti-
vated on the surface of endothelial cells – a process 
catalyzed by thrombin-thrombomodulin complex. 
EPCR further stimulates the PC activation (12). Our 
results show that the level of PC: Ag in the plasma 
of rats injected with melatonin was significantly re-
duced (Fig. 1A). This could be a manifestation of sup-
pressed PC biosynthesis (13). This statement contra-
dicts data from other sources, which claim that the 
liver holds primary significance in regard to the syn-
thesis of plasma coagulation factors. Furthermore, 




 have been 
identified in various mammalian tissues, including 
the liver in rats (14). Extrapolating from the current-
ly available data, at this stage it is difficult to deter-
mine the exact mechanism of manifestation of mela-
tonin’s suppressive effect. It is very likely that the pro-




 receptors, a 
fact that is supported by the observed increase in PC: 
Ag after administration of the non-selective melato-





 receptors in various tissues and 
organs (15), it is appropriate to assume the interven-
tion of other regulatory relationships and mecha-
nisms which mediate the effects of melatonin on PC: 
Ag. The three-day injection of melatonin in rats in-
duces a decrease of both the PC: Act, as well as APC 
(Fig. 1B, 1C). Although the concentration and activ-
ity of PC and APC are different indicators, pertain-
ing not only to synthesis but to the stages of PC acti-
vation, the observed changes in the three parameters 
are in the same direction and testify for a suppression 
of the activity of the anticoagulant PC pathway and a 
tendency to hypercoagulability.
EPCR is isolated and cloned as an endothelial 
cell-specific, highly selective and high-affinity bind-
Fig. 3. Effects of melatonin (0.2 mg/kg body weight), luzindole (0.4 mg/kg body weight) and melatonin 1 hour after pre-
treatment with luzindole (same dose), all administered s.c. to male Wistar rats, 2 times a day, for three consecutive days 
on the plasma levels of (free PS: Ag) (A) and (PS: Act) (B). Used abbreviations: C - control group injected saline;  
M - melatonin; L - luzindole. Data are presented as x ± S x , ***- p <0.001; **- p <0.01.
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ing protein for PC and APC (16). EPCR binds PC of 
the endothelial surface and provides it to the throm-
bin-thrombomodulin complex for activation. The 
soluble form sEPCR, which occurs in the proteolyt-
ic cleavage of the membrane-bound form can bind 
APC and deprive him of its anticoagulant function 
(17). In our study we found a significant increase of 
sEPCR (Fig. 2A). It is known, that sEPCR circulates 
in plasma and inactivates the anticoagulant activity 
of APC (17). The increased level of sEPCR in plasma 
correlates with the observed decrease in APC.
A crucial cofactor of the thrombin-mediated 
PC activation is thrombomodulin – a superficially 
expressed glycoprotein, synthesized in the vascular 
endothelium (18). Data describing the level of throm-
bomodulin in plasma are often contradictory. Ac-
cording to some authors, the reduced level is an ex-
pression of hypocoagulability, and increased level is a 
marker of endothelial dysfunction and hypercoagu-
lability (19,20). The three-day administration of mel-
atonin in our study (Fig. 2B) caused a reliable reduc-
tion in thrombomodulin, a result which correlates 
with the established changes in the levels of PC: Ag, 
PC: Act and APC and points towards suppression of 
the activity of the anticoagulant PC pathway.
The activated PC, together with its cofactor 
protein S, inhibits coagulation by irreversible proteo-
lytic inactivation of factor VIIIa and factor Va on the 
surface of the negatively charged phospholipid mem-
branes (21). After application of melatonin, a signif-
icant increase in the free protein S (Fig. 3A) as well 
as protein S (Fig. 3B) was established. These chang-
es could be an expression of stimulated biosynthesis 
of protein S in hepatocytes after treatment with mel-
atonin (13).
Luzindole is the first, but not the sole ligand, 
described as a receptor antagonist of melatonin (22). 
Standalone administration of luzindole in this study 
was followed by a significant increase in the levels of 
PC: Ag, PC: Act and APC (Fig. 1A, B, C). This re-
sult could be a manifestation of inhibition of melato-




 receptors. A sim-
ilar effect was also observed with respect to the lev-
el of thrombomodulin – luzindole significantly in-
creased its level (Fig. 2B). Thus, the present stimu-
lation of these key elements of the PC anticoagulant 
pathway is consistent with the suppression of the lev-
el of sEPCR (Fig. 2A) under the influence of the mel-
atonin receptor antagonist. Luzindole causes a sig-
nificant inhibition of free protein S (Fig. 3A) and its 
activity (Fig. 3B). From the presented results it is evi-
dent that the changes in all parameters after admin-
istration of luzindole are in opposite direction to the 
changes under the same parameters after melatonin 
application. The described changes in the key ele-
ments of the PC anticoagulant pathway under the in-
fluence of luzindole could be interpreted as evidence 




 receptors in accom-
plishing the effects of melatonin on coagulation.
Treatment of rats with melatonin, one hour af-
ter pretreatment with luzindole at the same dose and 
administration scheme, resulted in a statistically sig-
nificant increase (p<0.001) of APC and PC activity 
(Fig. 1B, C). In the same direction is the change in 
the PC antigen concentration (Fig. 1A), while the ob-
served increase was less pronounced (p <0.01). Pre-
treatment with luzindole causes also significant 
changes in endothelial receptors, which play a key 
role in the PC anticoagulant pathway, namely: sEP-
CR is reduced (Fig. 2A), while the thrombomodu-
lin level is increased (Fig. 2B). The effect on the lev-
els of free protein S and protein S activity results in a 
significant reduction (Fig. 3A, B). The presented re-
sults show that pretreatment with luzindole effec-
tively eliminates the observed effects of melatonin. 
Furthermore, treatment with melatonin after pre-
treatment with luzindole almost entirely repeates the 
changes in the studied parameters obtained after ad-
ministration of luzindole only. This fact allows us to 
assume that luzindole removes the effect of exoge-
nous melatonin. Especially noteworthy are the ob-
tained results for the following parameters: sEPCR, 
the levels of free protein S and protein S activity. The 
observed values  after administration of luzindole 
only, as well as in pretreatment with it, are lower than 
those of the control group of animals – a fact that 





 significantly blocks endog-
enous melatonin as well. Based on the described re-
sults we could assume a considerably more compli-




 in realizing the effects of 
melatonin. 
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CONCLUSIONS
The results presented above clearly indicate that 
melatonin significantly reduces the activity of the PC 
anticoagulation pathway in rats. The increased activ-
ity of this pathway, observed after administration of 
luzindole independently and prior to treatment with 





 membrane receptors removes the 
effect of both endogenous and exogenous melatonin. 
The significantly reduced activity of the PC antico-
agulant pathway can be regarded as one of the mech-
anisms by which this hormone causes an evident ten-
dency to hypercoagulability established in our previ-
ous studies (10, 11). Despite the experimental nature 
of the derived results, it is logical to raise the question 
of the necessity of preventive hemostasis control in 
both patients undergoing melatonin therapy(23-26), 
and patients receiving food supplements containing 
melatonin (27).
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